GlycoMimetics, Inc. (GKO.F)
| Previous Close | 0.2795 |
| Open | 0.2765 |
| Bid | 0.2735 x 100000 |
| Ask | 0.2900 x 100000 |
| Day's Range | 0.2765 - 0.2765 |
| 52 Week Range | 0.2705 - 3.1850 |
| Volume | |
| Avg. Volume | 591 |
| Market Cap | 17.821M |
| Beta (5Y Monthly) | 2.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5400 |
| Earnings Date | Jul 31, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.67 |
Business WireGlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
ROCKVILLE, Md., May 06, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced topline results from its Phase 3 global pivotal study of uproleselan in 388 patients with R/R AML. In the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemothera
Simply Wall St.We're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Business WireGlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
ROCKVILLE, Md., April 25, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET.
